ASH 2023 | The feasibility of consecutive day dosing of high-dose cytarabine consolidation in AML
Ashish Bajel, MBBS, FRACP, FRCPA, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia, discusses consecutive day dosing of high-dose cytarabine (HDAC) consolidation in patients with acute myeloid leukemia (AML). Traditionally, HDAC is administered on days 1, 3, and 5 (HDAC-135). However, Dr Bajel highlights that an HDAC-123 schedule was comparable in terms of safety and efficacy while resulting in financial savings due to lower resource utilization. This indicates that HDAC-123 is a feasible intensive chemotherapy consolidation approach in fit patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
